WO2006080412A3 - Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation - Google Patents

Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation Download PDF

Info

Publication number
WO2006080412A3
WO2006080412A3 PCT/JP2006/301258 JP2006301258W WO2006080412A3 WO 2006080412 A3 WO2006080412 A3 WO 2006080412A3 JP 2006301258 W JP2006301258 W JP 2006301258W WO 2006080412 A3 WO2006080412 A3 WO 2006080412A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
solid pharmaceutical
composition
pharmaceutical preparation
atom
Prior art date
Application number
PCT/JP2006/301258
Other languages
French (fr)
Other versions
WO2006080412A2 (en
Inventor
Hiroaki Yazaki
Hiroshi Ikuta
Original Assignee
Taisho Pharmaceutical Co Ltd
Hiroaki Yazaki
Hiroshi Ikuta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd, Hiroaki Yazaki, Hiroshi Ikuta filed Critical Taisho Pharmaceutical Co Ltd
Publication of WO2006080412A2 publication Critical patent/WO2006080412A2/en
Publication of WO2006080412A3 publication Critical patent/WO2006080412A3/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A composition for solid pharmaceutical preparations, essentially consisting of a cyanopyrrolidine derivative represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, and at least one stabilizing ingredient selected from the group consisting of sugars and sugar alcohols, [Formula 1] [wherein R1 represents, for example, a halogen atom or a hydroxyl group, R3 and R4 may be the same or different, each represents, for example, a hydrogen atom or a halogen atom, X represents an oxygen atom or a sulfur atom, Y represents, for example, a group represented by -CR5R6- (wherein R5 and R6 may be the same or different, each represents, for example, a hydrogen atom or a halogen atom), W represents, for example, a hydrogen atom or an acyl group derived from naturally occurring amino acids, and Z represents, for example, a hydrogen atom or an alkyl group of 1 to 10 carbon atoms which may be substituted with one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a hydroxylalkyl group of 1 to 5 carbon atoms, a carboxyl group, a mercapto group and the like].
PCT/JP2006/301258 2005-01-28 2006-01-20 Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation WO2006080412A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005022193A JP2008024592A (en) 2005-01-28 2005-01-28 Cyanopyrrolidine derivative-containing composition for solid preparation, solid preparation containing the composition and process for producing the solid preparation
JP2005-022193 2005-01-28

Publications (2)

Publication Number Publication Date
WO2006080412A2 WO2006080412A2 (en) 2006-08-03
WO2006080412A3 true WO2006080412A3 (en) 2006-09-21

Family

ID=36570928

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2006/301258 WO2006080412A2 (en) 2005-01-28 2006-01-20 Cyanopyrrolidine derivative-containing composition for solid pharmaceutical preparations, solid pharmaceutical preparation containing the composition, and process for producing the solid pharmaceutical preparation

Country Status (6)

Country Link
JP (1) JP2008024592A (en)
AR (1) AR052197A1 (en)
DO (1) DOP2006000019A (en)
PE (1) PE20061199A1 (en)
TW (1) TW200637815A (en)
WO (1) WO2006080412A2 (en)

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0280999A2 (en) * 1987-02-24 1988-09-07 Warner-Lambert Company Stabilized pharmaceutical compositions containing angiotensin-converting enzyme inhibitors
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
WO2001068603A2 (en) * 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
WO2001096295A2 (en) * 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
EP1333025A1 (en) * 2000-11-10 2003-08-06 Taisho Pharmaceutical Co., Ltd Cyanopyrrolidine derivatives
WO2003074500A2 (en) * 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2004009544A1 (en) * 2002-07-23 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. 2-cyano-4-fluoropyrrolidine derivative or its salt
WO2004020407A1 (en) * 2002-08-29 2004-03-11 Taisho Pharmaceutical Co.,Ltd. Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
US20040235752A1 (en) * 2001-06-25 2004-11-25 Pitt Gary Robert William 3-fluoro-pyrrolidines as antidiabetic agents
WO2005021536A2 (en) * 2003-08-29 2005-03-10 Sanofi-Aventis Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2005067976A2 (en) * 2004-01-20 2005-07-28 Novartis Ag Direct compression formulation and process

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0280999A2 (en) * 1987-02-24 1988-09-07 Warner-Lambert Company Stabilized pharmaceutical compositions containing angiotensin-converting enzyme inhibitors
WO2000034241A1 (en) * 1998-12-10 2000-06-15 Novartis Ag N-substituted 2-cyanopyrrolidines
WO2001068603A2 (en) * 2000-03-10 2001-09-20 Bristol-Myers Squibb Co. Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use
WO2001096295A2 (en) * 2000-06-13 2001-12-20 Novartis Ag 2-cyanopyrrolidine derivatives and their use as medicaments
EP1333025A1 (en) * 2000-11-10 2003-08-06 Taisho Pharmaceutical Co., Ltd Cyanopyrrolidine derivatives
US20040235752A1 (en) * 2001-06-25 2004-11-25 Pitt Gary Robert William 3-fluoro-pyrrolidines as antidiabetic agents
WO2003057144A2 (en) * 2001-12-26 2003-07-17 Guilford Pharmaceuticals Change inhibitors of dipeptidyl peptidase iv
WO2003074500A2 (en) * 2002-03-06 2003-09-12 Sanofi-Aventis N-aminoacetyl-pyrrolidine-2-carbonitriles and their use as ddp-iv inhibitors
WO2004009544A1 (en) * 2002-07-23 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. 2-cyano-4-fluoropyrrolidine derivative or its salt
EP1541551A1 (en) * 2002-07-23 2005-06-15 Yamanouchi Pharmaceutical Co. Ltd. 2-cyano-4-fluoropyrrolidine derivative or its salt
WO2004020407A1 (en) * 2002-08-29 2004-03-11 Taisho Pharmaceutical Co.,Ltd. Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
EP1535907A1 (en) * 2002-08-29 2005-06-01 Taisho Pharmaceutical Co., Ltd Benzenesulfonate of 4-fluoro-2-cyanopyrrolidine derivative
WO2005021536A2 (en) * 2003-08-29 2005-03-10 Sanofi-Aventis Adamantane and azabicyclo-octane and nonane derivatives, process of their preparation and their use as dpp-iv inhibitors
WO2005067976A2 (en) * 2004-01-20 2005-07-28 Novartis Ag Direct compression formulation and process

Also Published As

Publication number Publication date
DOP2006000019A (en) 2006-07-15
AR052197A1 (en) 2007-03-07
JP2008024592A (en) 2008-02-07
TW200637815A (en) 2006-11-01
WO2006080412A2 (en) 2006-08-03
PE20061199A1 (en) 2006-11-18

Similar Documents

Publication Publication Date Title
TW200616994A (en) Novel thiophene derivatives
CA2325045A1 (en) Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same
CA2510853A1 (en) Pyrrolopyrimidine derivatives
WO2007009656A3 (en) Novel 1,4-benzothiazepine-1,1-dioxide derivative having improved properties, method for the production thereof, medicaments containing said compound, and use thereof
EP1982982A4 (en) Novel coumarin derivative having antitumor activity
MY120842A (en) 1,4-benzothiazepine-1, 1-dioxide derivatives substituted by sugar residues, process for their preparation, pharmaceuticals comprising these compounds, and their use.
WO2004020431A3 (en) Novel benzoimidazole derivatives useful as antiproliferative agents
WO2009066775A1 (en) Amorphous form of heterocyclic compound, solid dispersion and medicinal preparation each comprising the same, and process for production of the same
NO20085060L (en) Triazole pyrazine derivatives useful as anti-cancer agents
WO2008012542A3 (en) Polysaccharide derivatives of erythropoietin
NO20056010L (en) Biaryloksymetylaren acids
WO2008120725A1 (en) Novel pyrrolinone derivative and medicinal composition containing the same
MY137039A (en) Thiophene glycoside derivatives, processes for the preparation, medicaments comprising these compounds, and the use thereof
WO2007072158A3 (en) Pyrimidine derivatives for the treatment of abnormal cell growth
HUP9702345A2 (en) 3-hydroxy-pyridine-2-carboxylic-amide-ester derivatives, process for producing them, pharmaceutical compositions containing them and their use
WO2006117211A3 (en) Urea derivatives methods for their manufacture and uses thereof
YU56402A (en) 8,8a-dihydro-indeno/1,2-d/thiazole derivatives with sulphonamido or sulphono substituent in the 2 position, a method for production thereof and use thereof as medicament
EP1634874A4 (en) Imidazolidine derivative
WO2004096823A3 (en) Novel ketolide derivatives
WO2007080270A3 (en) New cholest-4-en-3-one oxime derivatives, pharmaceutical compositions comprising them, and preparation process
CN105001289A (en) Eprinomectin refining method
WO2005033066A3 (en) Arylalkylcarbamate derivatives, preparation method thereof and use of same in therapeutics
WO2006112742A3 (en) PROCESS FOR PREPARATION OF 13,14-DIHYDRO-PGF2α DERIVATIVES
WO2006129168A3 (en) Bicyclic derivatives for the treatment of abnormal cell growth
EP1914229A4 (en) Novel cercosporamide derivative

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 06701436

Country of ref document: EP

Kind code of ref document: A2

WWW Wipo information: withdrawn in national office

Ref document number: 6701436

Country of ref document: EP